115 related articles for article (PubMed ID: 38719744)
1. The Metabolism and Disposition of Brepocitinib in Humans and Characterization of the Formation Mechanism of an Aminopyridine Metabolite.
Dowty ME; Qiu R; Dantonio A; Niosi M; Doran A; Balesano A; Wright SW; Walker GS; Sharma R
Drug Metab Dispos; 2024 Jun; 52(7):690-702. PubMed ID: 38719744
[TBL] [Abstract][Full Text] [Related]
2. Metabolism, excretion, and pharmacokinetics of [14C]INCB018424, a selective Janus tyrosine kinase 1/2 inhibitor, in humans.
Shilling AD; Nedza FM; Emm T; Diamond S; McKeever E; Punwani N; Williams W; Arvanitis A; Galya LG; Li M; Shepard S; Rodgers J; Yue TY; Yeleswaram S
Drug Metab Dispos; 2010 Nov; 38(11):2023-31. PubMed ID: 20699411
[TBL] [Abstract][Full Text] [Related]
3. Absorption, Distribution, Metabolism, and Excretion of Capmatinib (INC280) in Healthy Male Volunteers and In Vitro Aldehyde Oxidase Phenotyping of the Major Metabolite.
Glaenzel U; Jin Y; Hansen R; Schroer K; Rahmanzadeh G; Pfaar U; Jaap van Lier J; Borell H; Meissner A; Camenisch G; Zhao S
Drug Metab Dispos; 2020 Oct; 48(10):873-885. PubMed ID: 32665418
[TBL] [Abstract][Full Text] [Related]
4. Biotransformation Pathways and Metabolite Profiles of Oral [
Pusalkar S; Zhou X; Li Y; Cohen L; Yang JJ; Balani SK; Xia C; Shyu WC; Lu C; Venkatakrishnan K; Chowdhury SK
Drug Metab Dispos; 2020 Mar; 48(3):217-229. PubMed ID: 31911485
[TBL] [Abstract][Full Text] [Related]
5. The Pharmacokinetics, Metabolism, and Clearance Mechanisms of Abrocitinib, a Selective Janus Kinase Inhibitor, in Humans.
Bauman JN; Doran AC; King-Ahmad A; Sharma R; Walker GS; Lin J; Lin TH; Telliez JB; Tripathy S; Goosen TC; Banfield C; Malhotra BK; Dowty ME
Drug Metab Dispos; 2022 Aug; 50(8):1106-1118. PubMed ID: 35701182
[TBL] [Abstract][Full Text] [Related]
6. Metabolism and Disposition of Siponimod, a Novel Selective S1P
Glaenzel U; Jin Y; Nufer R; Li W; Schroer K; Adam-Stitah S; Peter van Marle S; Legangneux E; Borell H; James AD; Meissner A; Camenisch G; Gardin A
Drug Metab Dispos; 2018 Jul; 46(7):1001-1013. PubMed ID: 29735753
[TBL] [Abstract][Full Text] [Related]
7. Metabolism and Disposition of Pacritinib (SB1518), an Orally Active Janus Kinase 2 Inhibitor in Preclinical Species and Humans.
Jayaraman R; Pasha MK; Williams A; Goh KC; Ethirajulu K
Drug Metab Lett; 2015; 9(1):28-47. PubMed ID: 25600203
[TBL] [Abstract][Full Text] [Related]
8. The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a janus kinase inhibitor, in humans.
Dowty ME; Lin J; Ryder TF; Wang W; Walker GS; Vaz A; Chan GL; Krishnaswami S; Prakash C
Drug Metab Dispos; 2014 Apr; 42(4):759-73. PubMed ID: 24464803
[TBL] [Abstract][Full Text] [Related]
9. Excretion, metabolism, and pharmacokinetics of 1-(8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl)-4-(ethylamino)piperidine-4-carboxamide, a selective cannabinoid receptor antagonist, in healthy male volunteers.
Miao Z; Sun H; Liras J; Prakash C
Drug Metab Dispos; 2012 Mar; 40(3):568-78. PubMed ID: 22187487
[TBL] [Abstract][Full Text] [Related]
10. Absorption, Metabolism, Excretion, and the Contribution of Intestinal Metabolism to the Oral Disposition of [14C]Cobimetinib, a MEK Inhibitor, in Humans.
Takahashi RH; Choo EF; Ma S; Wong S; Halladay J; Deng Y; Rooney I; Gates M; Hop CE; Khojasteh SC; Dresser MJ; Musib L
Drug Metab Dispos; 2016 Jan; 44(1):28-39. PubMed ID: 26451002
[TBL] [Abstract][Full Text] [Related]
11. Absorption, metabolism, and excretion of oral ¹⁴C radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men.
Scheers E; Leclercq L; de Jong J; Bode N; Bockx M; Laenen A; Cuyckens F; Skee D; Murphy J; Sukbuntherng J; Mannens G
Drug Metab Dispos; 2015 Feb; 43(2):289-97. PubMed ID: 25488930
[TBL] [Abstract][Full Text] [Related]
12. Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human.
Su H; Boulton DW; Barros A; Wang L; Cao K; Bonacorsi SJ; Iyer RA; Humphreys WG; Christopher LJ
Drug Metab Dispos; 2012 Jul; 40(7):1345-56. PubMed ID: 22496391
[TBL] [Abstract][Full Text] [Related]
13. Metabolism, excretion, and pharmacokinetics of ((3,3-difluoropyrrolidin-1-yl)((2S,4S)-4-(4-(pyrimidin-2-yl)piperazin-1-yl)pyrrolidin-2-yl)methanone, a dipeptidyl peptidase inhibitor, in rat, dog and human.
Sharma R; Sun H; Piotrowski DW; Ryder TF; Doran SD; Dai H; Prakash C
Drug Metab Dispos; 2012 Nov; 40(11):2143-61. PubMed ID: 22896728
[TBL] [Abstract][Full Text] [Related]
14. A phase 1 study to investigate the absorption, distribution, metabolism and excretion of brepocitinib in healthy males using a
Qiu R; Sharma R; Wei H; Kirkovsky L; Zhou Y; Martin DDA; Banfield C; Dowty ME
Br J Clin Pharmacol; 2023 Oct; 89(10):3056-3066. PubMed ID: 37183779
[TBL] [Abstract][Full Text] [Related]
15. Excretion and metabolism of lersivirine (5-{[3,5-diethyl-1-(2-hydroxyethyl)(3,5-14C2)-1H-pyrazol-4-yl]oxy}benzene-1,3-dicarbonitrile), a next-generation non-nucleoside reverse transcriptase inhibitor, after administration of [14C]Lersivirine to healthy volunteers.
Vourvahis M; Gleave M; Nedderman AN; Hyland R; Gardner I; Howard M; Kempshall S; Collins C; LaBadie R
Drug Metab Dispos; 2010 May; 38(5):789-800. PubMed ID: 20124396
[TBL] [Abstract][Full Text] [Related]
16. Metabolism and Mass Balance of the Novel Nonsteroidal Androgen Receptor Inhibitor Darolutamide in Humans.
Taavitsainen P; Prien O; Kähkönen M; Niehues M; Korjamo T; Denner K; Nykänen P; Vuorela A; Jungmann NA; von Bühler CJ; Koskinen M; Zurth C; Gieschen H
Drug Metab Dispos; 2021 Jun; 49(6):420-433. PubMed ID: 33785516
[TBL] [Abstract][Full Text] [Related]
17. Mass balance, metabolic disposition, and pharmacokinetics of [
Zhou S; Liu W; Zhou C; Zhang L; Xie L; Xu Z; Wang L; Zhao Y; Guo L; Chen J; Ding L; Mao L; Tao Y; Zhang C; Ding S; Shao F
Cancer Chemother Pharmacol; 2020 Dec; 86(6):719-730. PubMed ID: 33044566
[TBL] [Abstract][Full Text] [Related]
18. The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF-06700841) in Healthy Subjects and Patients With Plaque Psoriasis.
Banfield C; Scaramozza M; Zhang W; Kieras E; Page KM; Fensome A; Vincent M; Dowty ME; Goteti K; Winkle PJ; Peeva E
J Clin Pharmacol; 2018 Apr; 58(4):434-447. PubMed ID: 29266308
[TBL] [Abstract][Full Text] [Related]
19. Assessment of the drug interaction risk for remogliflozin etabonate, a sodium-dependent glucose cotransporter-2 inhibitor: evidence from in vitro, human mass balance, and ketoconazole interaction studies.
Sigafoos JF; Bowers GD; Castellino S; Culp AG; Wagner DS; Reese MJ; Humphreys JE; Hussey EK; O'Connor Semmes RL; Kapur A; Tao W; Dobbins RL; Polli JW
Drug Metab Dispos; 2012 Nov; 40(11):2090-101. PubMed ID: 22851617
[TBL] [Abstract][Full Text] [Related]
20. Mass Balance and Metabolic Pathways of Eliapixant, a P2X3 Receptor Antagonist, in Healthy Male Volunteers.
Reif S; Schultze-Mosgau MH; Engelen A; Piel I; Denner K; Roffel A; Tiessen R; Klein S; Francke K; Rottmann A
Eur J Drug Metab Pharmacokinet; 2024 Jan; 49(1):71-85. PubMed ID: 38044419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
